Diagnostic and therapeutic management of Churg-Strauss syndrome

Julia U. Holle, Frank Moosig, Wolfgang L. Gross

6 Citations (Scopus)


Churg-Strauss syndrome is a rare small-vessel vasculitis that is associated with asthma, granulomatous inflammation, peripheral/tissue eosinophilia and a positive antineutrophil cytoplasmic antibody status (in approximately 40% of patients). The disease can be organ- and life-threatening, either due to tissue eosinophil infiltration such as myocarditis or due to vasculitis manifestations, for example glomerulonephritis. Furthermore, life-threatening disease can also occur due to the side effects of immunosuppression, for example, infection. A thorough diagnostic work-up should be performed in order to identify all organs involved and to rule out other disorders with similar features, such as hypereosinophilic syndrome. Therapeutic management is conducted according to disease stage and activity. Glucocorticoids remain the mainstay of therapy; however, further immunosuppressants (e.g., cyclophosphamide for life-threatening disease) are usually required. Future promising therapy options target cytokines involved in the disease process, such as IL-5.

Original languageEnglish
JournalExpert Review of Clinical Immunology
Issue number6
Pages (from-to)813-823
Number of pages11
Publication statusPublished - 11.2009

Research Areas and Centers

  • Academic Focus: Center for Infection and Inflammation Research (ZIEL)


Dive into the research topics of 'Diagnostic and therapeutic management of Churg-Strauss syndrome'. Together they form a unique fingerprint.

Cite this